Allogeneic Mesenchymal Cells in Clinical Practice: Case Studies and Scientific Evidence
Clinical Cases and Advances in Cell Therapies with Allogeneic Mesenchymal Stromal Cells
Regenerative medicine has opened new possibilities for treating inflammatory and degenerative diseases, and allogeneic mesenchymal stem cells (MSC) have shown remarkable potential in clinical studies. In this article, we explore key clinical cases that supported the approval of MSC-based treatments in the United States, South Korea, and Japan.
Case Study 1: RYONCIL and Pediatric Graft-versus-Host Disease (GVHD)
A study published in Biology of Blood and Marrow Transplantation analyzed the effectiveness of RYONCIL (remestemcel-L) in children with severe steroid-refractory GVHD. In this multicenter trial, 55 pediatric patients received MSC infusions. After 4 weeks, 69% of patients showed significant clinical improvement, and after 12 weeks, the survival rate reached 78%.
This case study was crucial for FDA approval in 2020, as it provided an effective alternative for patients with high mortality risk.
Case Study 2: CARTISTEM and Cartilage Regeneration in Osteoarthritis
In South Korea, CARTISTEM was approved in 2012 based on a clinical trial involving 128 patients with severe knee osteoarthritis. Patients received an injection of umbilical cord-derived MSCs into the affected joint.
After 12 months, MRI scans showed structural cartilage regeneration in 80% of patients, and improvements in pain and mobility lasted up to 7 years in follow-up studies. This breakthrough allowed CARTISTEM to become a standard treatment for cartilage regeneration in South Korea.
Case Study 3: TEMCELL and GVHD Treatment in Adults in Japan
In Japan, TEMCELL (remestemcel-L) was approved in 2015 for treating acute GVHD in adults. The key evidence came from a clinical trial where 25 patients received TEMCELL after failing conventional immunosuppressive therapy.
The study showed that 61% of patients experienced a positive response within the first 4 weeks, with significant inflammation reduction and decreased need for additional immunosuppressive therapy.
Japan’s fast-track regulatory model for cellular therapies enabled TEMCELL to reach clinical practice quickly, benefiting patients with limited treatment options.
Conclusion: From Scientific Evidence to Clinical Practice
The reviewed case studies demonstrate the real-world impact of allogeneic mesenchymal stem cells in modern medicine. These therapies have transformed treatment paradigms across different medical fields, from RYONCIL for pediatric GVHD to CARTISTEM in cartilage regeneration and TEMCELL for severe autoimmune conditions.
At Baja Regenerative, we remain committed to staying at the forefront of regenerative medicine and providing access to therapies backed by the best available scientific evidence.
References
- S. Food and Drug Administration.RYONCIL (remestemcel-L) – FDA Approval. Silver Spring, MD: FDA; 2020. Available from: https://www.fda.gov/
- Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, et al.Allogeneic human mesenchymal stem cell therapy (remestemcel-L) for pediatric patients with steroid-refractory acute graft-versus-host disease: updated outcomes. Biol Blood Marrow Transplant. 2020;26(8):1578-83. doi:10.1016/j.bbmt.2020.03.014
- Korean Ministry of Food and Drug Safety (MFDS).Approval of CARTISTEM for osteoarthritis treatment. Seoul, South Korea: MFDS; 2012. Available from: https://www.mfds.go.kr/
- Park YB, Ha CW, Lee CH, Yoon YC, Park YG.Cartistem injection in patients with knee osteoarthritis: a long-term follow-up study. Am J Sports Med. 2021;49(5):1220-30. doi:10.1177/0363546520988746
- Pharmaceuticals and Medical Devices Agency (PMDA).TEMCELL HS Inj. Approval Report. Tokyo, Japan: PMDA; 2015. Available from: https://www.pmda.go.jp/
- Kuroda R, Matsumoto T, Niikura T, Kawakami Y, Fukui T, Lee SY, et al.Regenerative therapy using mesenchymal stem cells in Japan: Current status and future perspectives. Stem Cells Transl Med. 2022;11(4):456-65. doi:10.1093/stcltm/szac005
